GPRC5D-Directed Antibodies in Multiple Myeloma: New Agents and Frontline Strategies From IMS 2026
Clinical Lymphoma Myeloma and Leukemia · 2026-10
DOI: 10.1016/j.clml.2026.10.017 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-10. Verfasst von Changnian Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China. Die Arbeit nennt 9 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
- Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China. Electronic address: csytcm@126.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, C., & Cui, S. (2026). GPRC5D-Directed Antibodies in Multiple Myeloma: New Agents and Frontline Strategies From IMS 2026. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.10.017
Vancouver
Li C, Cui S. GPRC5D-Directed Antibodies in Multiple Myeloma: New Agents and Frontline Strategies From IMS 2026. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.10.017
BibTeX
@article{Li2026,
author = {Li, Changnian and Cui, Siyuan},
title = {GPRC5D-Directed Antibodies in Multiple Myeloma: New Agents and Frontline Strategies From IMS 2026},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
doi = {10.1016/j.clml.2026.10.017}
}
EUVIMED